BioCryst to discontinue development of drug
Shares of BioCryst Pharmaceuticals Inc. were down about 5% in premarket trading on Thursday after the company said it…
7,310€
2,37%
Echtzeit-Aktienkurs BioCryst Pharmaceuticals
Bid:
Ask:
Nachrichten zur BioCryst Pharmaceuticals Aktie
BioCryst Shares Fall Premarket After BCX9930 Program Scrapped >BCRX
BioCryst Shares Fall Premarket After BCX9930 Program Scrapped >BCRX...…
Form 8-K BIOCRYST PHARMACEUTICALS For: Dec 15
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…
BioCryst to Present at JMP Securities Hematology & Oncology Summit
RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…
Insiderhandel: President & CEO verkauft Aktien von BioCryst Pharmaceuticals im Wert von 2.793.921$
Stonehouse, Jon P. - Vorstand - Tag der Transaktion: 2022-12-01...…
Insiderhandel: Exec. Director, Finance - PAO verkauft Aktien von BioCryst Pharmaceuticals im Wert von 111.886$
Jones, Michael L. - Vorstand - Tag der Transaktion: 2022-12-01...…
Insiderhandel: President & CEO verkauft Aktien von BioCryst Pharmaceuticals im Wert von 1.057.997$
Stonehouse, Jon P. - Vorstand - Tag der Transaktion: 2022-12-02...…
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Israeli Ministry of Health
RESEARCH TRIANGLE PARK, N.C., Nov. 28, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…
BioCryst Presents Real-World Data Showing Rapid and Sustained HAE Attack Rate Reduction After Beginning ORLADEYO® (berotralstat), Regardless of Prior Prophylactic Therapy
RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world…
Form 10-Q BIOCRYST PHARMACEUTICALS For: Sep 30
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
4 Analysts Have This to Say About BioCryst Pharmaceuticals
Within the last quarter, BioCryst Pharmaceuticals (NASDAQ:BCRX) has observed the following analyst ratings:
Latest Ratings for BCRX
…
BioCryst Pharmaceuticals (BCRX) Q3 2022 Earnings Call Transcript
BCRX earnings call for the period ending September 30, 2022....…
BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates
BioCryst (BCRX) delivered earnings and revenue surprises of 28.13% and 3.23%, respectively, for the quarter ended September 2022. Do the…
BioCryst Pharmaceuticals Q3 2022 Earnings Preview
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
RESEARCH TRIANGLE PARK, N.C., Oct. 24, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…
BioCryst to Report Third Quarter 2022 Financial Results on November 1
RESEARCH TRIANGLE PARK, N.C., Oct. 18, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., Oct. 04, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…
Got $3,000? Here Are 2 Stocks That Will Make You Richer
BioCryst Pharmaceuticals and Steris could both deliver outstanding returns for patient shareholders....…